美国BioVascular Inc
BioVascular公司是一家私人持股公司，开发生物技术药物和设备的控制内膜增生与血管有关的程序和控制的危险因素与心血管发病率和死亡率。BioVascular的主导产品， saratin ，是一种多肽生产中酵母重组手段。该产品是授权默克制药公司于2005年。 BioVascular开始人体临床试验的saratin血液透析移植准入和在2006年年底将开始人体试验治疗周围动脉移植在2007年年初。

BioVascular的第二个产品利用了一种新型机制，减少了最近界定心血管危险因素。该产品将进入人体试验阶段在2007年年中。
BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality.

BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007.

BioVascular’s second product utilizes a novel mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.